Single-domain antibodies as therapeutics for solid tumor treatment

Wang, Mingkai; Ying, Tianlei; Wu, Yanling

doi:10.1016/j.apsb.2024.03.016

Acta Pharmaceutica Sinica B

2024

DOI: 10.1016/j.apsb.2024.03.016

|View full text |Cite

Single-domain antibodies as therapeutics for solid tumor treatment

Mingkai Wang,

Tianlei Ying,

Yanling Wu

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 161 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction

Wang,

Yu,

You

et al. 2025

Bioactive Materials

View full text Add to dashboard Cite

Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction

Wang,

Yu,

You

et al. 2025

Bioactive Materials

View full text Add to dashboard Cite

Nanobody-as versatile tool emerging in autoimmune diseases

Wang,

Luo,

Zhang

et al. 2024

Smart Materials in Medicine

View full text Add to dashboard Cite

Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications

Li,

Zhan,

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

In the pharmaceutical industry, the Chinese hamster ovary cell, a type of mammalian cell, is extensively employed for the production of conventional full-length monoclonal antibodies. Nanobody is one of the most attractive directions for the development of next-generation antibody drugs. However, a suitable expression system for its manufacture has not yet been comprehensively evaluated. Previously, we proposed that the immunoglobulin constant CH2 domain could be a promising scaffold for developing C-type nanoantibodies (C-Nabs) as candidate therapeutics. Here, we used an antiviral C-Nab, which we identified previously (under review), as a model for investigation. We expressed C-Nabs without a tag in different systems, including a bacterium (C-Nab bac ), yeast (C-Nab yeast ), and mammalian cell (C-Nab mam ). After purification, the binding and neutralizing activities of C-Nabs from different expression systems are similar. Their secondary structures are rich in βstrand. The melting temperatures of C-Nab bac (71.5 °C) and C-Nab mam (70.2 °C) are similar, which are slightly higher than that of C-Nab yeast (65.6 °C), while C-Nab yeast and C-Nab mam are more resistant to urea-induced unfolding than C-Nab bac . C-Nab yeast and C-Nab mam demonstrate higher resistance to aggregation compared to C-Nab bac . C-Nab yeast exhibits greater resistance to enzyme digestion compared to C-Nab bac and C-Nab mam . Notably, when administered via intraperitoneal injection in mice, C-Nab yeast shows superior pharmacokinetics. Overall, after comparing C-Nab proteins from various expression systems, we determined that yeast is the most suitable host for producing C-Nabs. This finding is beneficial for the production of nanobodies as potential drug candidates.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Single-domain antibodies as therapeutics for solid tumor treatment

Cited by 5 publications

References 161 publications

Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction

Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction

Nanobody-as versatile tool emerging in autoimmune diseases

Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications

Contact Info

Product

Resources

About